We recently reported that, compared to loxoprofen (LOX, an non-steroidal anti-inflammatory drug), the LOX derivative fluoro-loxoprofen (F-LOX) is less ulcerogenic but has similar anti-inflammatory activity. Our previous in vitro studies suggested that both LOX and F-LOX are pro-drugs, the active metabolites of which are their trans-alcohol forms. In this study, we compared the pharmacokinetics of F-LOX and LOX in rats. Overall, the pharmacokinetic characteristics of F-LOX, including the formation of metabolites in vivo and in vitro, were comparable to those of LOX. However, F-LOX disappeared from the plasma more rapidly than LOX, which could potentially explain its lower ulcerogenicity. However, we showed that F-LOX produced fewer gastric lesions than LOX, even when a higher plasma concentration of F-LOX was maintained. Similar to LOX, F-LOX was readily metabolized to its trans-and cis-alcohol forms, with a higher level of the trans-alcohol form being observed after oral or intravenous administration of the drug. The preferential formation of the trans-alcohol form was also observed after incubation of F-LOX with rat liver homogenates in vitro. These results suggest that, similar to LOX, F-LOX acts as a pro-drug and that there is a metabolic system that selectively produces its active metabolite.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) comprise a useful family of therapeutics, 1) the actions of which are mediated via an inhibitory effect on cyclooxygenase (COX), an enzyme which is essential for the synthesis of inflammatory prostaglandins (PGs). However, NSAID use is also associated with gastrointestinal complications. [2] [3] [4] Given that PGs have a strong protective effect on the gastric mucosa, it was believed that NSAIDs induce gastric lesions only through the inhibition of COX. However, the increased incidence of gastrointestinal lesions and the decrease in PG levels induced by NSAIDs do not always occur in parallel, 5, 6) suggesting that the former effect involves additional mechanisms. We have recently demonstrated that NSAIDs induce cell death in cultured gastric mucosal cells and at the gastric mucosa in a manner independent of COX inhibition but dependent on their membrane permeabilizing activity. [7] [8] [9] [10] [11] [12] [13] Furthermore, we suggested that both COX inhibition and gastric mucosal cell death are required for the formation of NSAID-induced gastric lesions. 11, 14) COX-1 and COX-2 are responsible for the majority of COX activity at the gastric mucosa and in tissues undergoing inflammation, respectively, 15, 16) and a greatly reduced incidence of gastroduodenal lesions has been reported following treatment with selective COX-2 inhibitors (such as celecoxib and rofecoxib). 17, 18) However, a recently raised concern regarding the use of selective COX-2 inhibitors involves the associated risk of cardiovascular thrombotic events. 19) This may be due to the fact that prostacyclin, a potent anti-aggregator of platelets and a vasodilator, is mainly produced by COX-2. Therefore, NSAIDs exhibiting gastrointestinal safety, other than selective COX-2 inhibitors, need to be developed. Based on our findings, we proposed that NSAIDs with lower membrane permeabilization activity would be easy on the stomach even in the absence of COX-2 selectivity. 9) We screened for such NSAIDs from those used clinically and found that loxoprofen (LOX, Fig. 1 ) has lower membrane permeabilization activity and cytotoxicity than other NSAIDs. 20) LOX has been widely used in the Japanese market, because clinical studies have suggested that it is safer than other traditional NSAIDs, such as indomethacin. 21, 22) LOX is a pro-drug, which is converted (by reduction of the cyclopentanone moiety) to its active transalcohol metabolite (trans-LOX-OH, Fig. 1 ) by multiple aldehydeketone reductases and carbonyl reductases only after absorption by the gastrointestinal tract. 23, 24) We synthesized a series of LOX derivatives 25) and found that fluoro-loxoprofen (F-LOX, Fig. 1 ) has much lower membrane permeabilization and ulcerogenic activities than LOX but maintains similar anti-inflammatory activity. 26) We also suggested that the pro-drug property of LOX is maintained in F-LOX, based on the demonstration that the inhibitory activity of trans-F-LOX-OH (Fig. 1) on COX is more potent than that of F-LOX and its cis-alcohol metabolite (cis-F-LOX-OH, Fig. 1 ).
26)
In this study, we compared the pharmacokinetics of LOX and F-LOX after oral or intravenous administration. Although some differences were observed, such as the more efficient absorption of F-LOX after its oral administration and its more rapid clearance from the plasma, the pharmacokinetic characters of F-LOX were basically comparable to those of LOX, including preferential metabolic formation of trans-F-LOX-OH rather than cis-F-LOX-OH. We therefore consider that F-LOX is likely to be a therapeutically beneficial NSAID due to its reduced gastric side effect.
Methods

Chemicals and animals:
The sodium salts of LOX and F-LOX and their alcohol metabolites (trans-LOX-OH, cis-LOX-OH, trans-F-LOX-OH and cis-F-LOX-OH) were synthesized as reported previously 26) and their identities were confirmed by 1 H-NMR, 13 C-NMR, FAB-MS spectrum and elemental analysis (within « 0.4% of the theoretical values). The purity of each tested compound was greater than 95% as assessed by high performance liquid chromatography (HPLC).
HPLC-grade acetonitrile was purchased from Sigma-Aldrich (St. Louis, MO). Wistar rats (6 weeks old, 180-200 g, male) were obtained from Kyudo Co. (Kumamoto, Japan). The experiments and procedures described here were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health (Bethesda, MD), and were approved by the Animal Care Committee of Keio University and Kumamoto University.
HPLC analysis: The analytical HPLC with reverse-phase column (TSKgel Super-ODS, 150 © 4.6 mm, 2 µm, Tosoh Co., Tokyo, Japan) incorporated a Waters 2695 Alliance separation module and a Waters 2996 photodiode array detector (Waters, Milford, MA). Solvent A (0.1% trifluoroacetic acid in acetonitrile) and solvent B (0.1% trifluoroacetic acid in water) were used at a flow rate of 0.3 ml/min. After injection of the sample (0 min), the mobile phase was changed as follows: 35% solvent A (10 min), a linear gradient of 35-100% solvent A (3 min) and 100% solvent A (3 min). Detection was performed at an optical density of 220 nm.
Drug administration and pharmacokinetic analysis: Each compound was dissolved in saline and administered to rats at a dose of 20 mg/kg, orally or intravenously (via the tail vein). Tail vein blood samples (200 µl) were taken periodically (15, 30, 45 , 60, 120 and 240 min after drug administration) into centrifuge tubes containing heparin. Samples were centrifuged immediately to obtain plasma. An aliquot (100 µl) of plasma was mixed with 500 µl of methanol to extract each compound and its metabolites. The suspension was centrifuged and the supernatant was analyzed by HPLC as described above.
Pharmacokinetic data analysis: A non-compartment model was used for the pharmacokinetic analysis. Each parameter, time of maximum concentration (T max , min), maximum concentration (C max , µg/ml), apparent elimination half-life (t 1/2 , min), area under the concentration-time curve from time 0 to infinite times (AUC 0-¨, µg/ml/min), mean residence time from time 0 to infinite times (MRT 0-¨, min), total plasma clearance (CL tot , ml/min/kg) and volume of distribution at the steady state (Vd ss , ml), was calculated using the moment analysis program available on Microsoft Excel. The absolute oral bioavailability (F, %) was calculated using the following equation:
Drug treatment of rat liver homogenates in vitro: In vitro analysis for metabolic conversion of F-LOX and LOX was performed as described previously, 27) with some modifications. Rat livers were homogenized with PBS (1 ml PBS/g tissue) using a tissue homogenizer (Silent Crusher M, Heidolph, Germany). Each test compound in PBS (100 µl, 5 mg/ml) was mixed with 2 ml of the homogenates and incubated for various periods (10, 20, 30 , 60, 120 and 240 min) at 37°C. The reaction was terminated by addition of 1.8 ml of methanol and the solution was centrifuged. The supernatant was analyzed by HPLC as described above.
Gastric damage assay: The gastric ulcerogenic response was examined as described previously, 25, 28) with some modifications. Rats fasted for 18 h were orally administered LOX or F-LOX and, after 8 h, the animals were sacrificed, their stomachs were removed, and the areas of gastric mucosal lesions were measured by an observer unaware of the treatment that the animals had received. Calculation of the scores involved measuring the area of all the lesions in square millimeters and summing the values to give an overall lesion index.
Statistical analysis: All values are expressed as the mean « S.D. or mean « S.E.M. One-way or two-way analysis of variance (ANOVA) followed by the Tukey's test was used to evaluate differences among more than three groups. The Student's t-test for unpaired results was used for the evaluation of differences between two groups. Differences were considered to be significant for values of p < 0.05.
Results and Discussion
Pharmacokinetic analysis after oral or intravenous administration of LOX or F-LOX: We first compared the temporal profile of the plasma concentration following oral administration of Figs. 2A and 2B ) and calculated the pharmacokinetic parameters based on moment analysis (non-compartment model) ( Table 1 ). The pharmacokinetic characteristics of LOX (Fig. 2) were basically similar to those described previously, 27) and in general, the pharmacokinetic characteristics of F-LOX were comparable to those of LOX, as described below.
The C max of F-LOX was significantly higher than that of LOX ( Table 1 ), suggesting that F-LOX was absorbed more rapidly at the gastrointestinal mucosa. However, F and T max values were not different between both F-LOX and LOX ( Table 1) . This may be due to the fact that the clearance of F-LOX is faster than LOX (see below).
The plasma level of F-LOX following oral administration (at 2 or 4 h) was lower than that of LOX ( Figs. 2A and 2B ) and the MRT 0-¨a nd t 1/2 of the former drug were shorter ( Table 1) . We concluded that F-LOX was cleared from the plasma more rapidly than LOX. The AUC 0-¨o f F-LOX following oral administration was smaller than that of LOX ( Table 1) .
We also monitored the temporal profile of the plasma concentrations of metabolites of LOX or F-LOX (trans-LOX-OH and cis-LOX-OH or trans-F-LOX-OH and cis-F-LOX-OH) after their oral administration and found that, similar to LOX, F-LOX was readily metabolized (Figs. 2A and 2B) . As previously described, 24, 27, 29) a relatively higher plasma level of trans-LOX-OH than cis-LOX-OH was observed (Fig. 2A) . Similar results were observed for F-LOX (Fig. 2B) . It is well known that LOX is metabolized to trans-or cis-LOX-OH with a stereoselectivity and multiple enzymes are involved in this stereoselectivity in humans. 24, 30) Results in this study suggest that the system for this stereoselective reduction is common between rats and humans, which was suggested by the previous paper. 31, 32) The C max of trans-F-LOX-OH (active metabolite) after oral administration of F-LOX was similar to that of LOX ( Table 1) . However, the t 1/2 and and AUC 0-¨o f trans-F-LOX-OH were shorter and smaller, respectively, than those of LOX ( Table 1) . We also calculated each pharmacokinetic parameter of cis-LOX-OH and cis-F-LOX-OH (Table 1) ; however, as the plasma level of each cis-OH form was very low, the accuracy of these results is debatable.
We also compared the plasma concentration-time profiles of LOX and F-LOX following their intravenous administration (Figs. 2C and 2D) . As in the case of oral administration, the MRT 0-¨a nd t 1/2 of F-LOX were shorter than those of LOX (Table 1) , confirming the more rapid plasma clearance of the former drug. Compared to LOX, CL tot of F-LOX after its intravenous administration tended to be higher, although this difference was not statistically significant ( Table 1) . The preferential conversion of F-LOX or LOX to its trans-OH rather than cis-OH form was also confirmed following intravenous administration (Figs. 2C and 2D) .
Pharmacokinetic analysis after administration of the transand cis-OH forms of LOX and F-LOX: We next compared the plasma concentration-time profile of each form of LOX and F-LOX after oral or intravenous administration of the trans-or Figure 2 were used to calculate each pharmacokinetic parameter as described in Methods. Values are mean « S.D. (n = 4-6). *p < 0.05, **p < 0.01 (vs. LOX and its metabolites). Figures 3 and 4 , LOX was detected after oral or intravenous administration of trans-LOX-OH or cis-LOX-OH. trans-LOX-OH was detected after oral or intravenous administration of cis-LOX-OH; however, cis-LOX-OH was not detected after oral or intravenous administration of trans-LOX-OH (Figs. 3 and 4) . These results are consistent with those reported previously. 33) Similar results were also observed for F-LOX (Figs. 3 and 4) , suggesting that there is a metabolic system which converts trans-or cis-F-LOX-OH to F-LOX. Our results also support the idea that the metabolic system converts F-LOX preferentially to trans-F-LOX-OH rather than to cis-F-LOX-OH, the assumption being that trans-F-LOX-OH is produced from cis-F-LOX-OH via F-LOX.
Data in
cis-OH form. As shown in
The data in Table 2 show that the C max of trans-F-LOX-OH was less than that of trans-LOX-OH following their oral administration, suggesting that the absorption of trans-F-LOX-OH was slower, in contrast to the situation with the ketone forms of these NSAIDs (Table 1) . However, the t 1/2 and MRT 0-¨o f trans-F-LOX-OH were shorter than those of trans-LOX-OH following both oral and intravenous administration ( Table 2) , this being consistent with what is observed in the case of their ketone forms ( Table 1) .
The data in Table 3 show that the pharmacokinetic characteristics of cis-F-LOX-OH, relative to cis-LOX-OH, differed from those of F-LOX and trans-F-LOX-OH. For example, the MRT 0-ö f cis-F-LOX-OH was longer than that of cis-LOX-OH after oral administration and AUC 0-¨o r CL tot of cis-F-LOX-OH was higher or lower than that of cis-LOX-OH after intravenous administration (Table 3) . However, as the cis-OH forms of F-LOX and LOX are inactive in terms of COX-inhibition, 26) these results may not be clinically or pharmacologically relevant. 
Metabolic conversion of F-LOX and LOX in vitro:
It has previously been reported that LOX is metabolized in the liver in vivo and that the conversion of LOX to trans-or cis-LOX-OH can be reproduced in vitro using rat liver homogenates. 34) Using this system, we examined the conversion of F-LOX to its trans-or cis-OH form in vitro. We first showed that incubation of LOX with rat liver homogenates produced a higher level of trans-LOX-OH than cis-LOX-OH (Fig. 5A) . Although both trans-LOX-OH and cis-LOX-OH were more stable than LOX in this system, incubation of trans-LOX-OH or cis-LOX-OH with the homogenates generated only LOX or both LOX and trans-LOX-OH, respectively (Figs. 5A-5C ). These results are consistent with those previously reported. 34) As shown in Figures 5D-5F , results obtained with F-LOX were essentially similar to those seen with LOX. Incubation of F-LOX with rat liver homogenates produced a higher level of trans-F-LOX-OH than cis-F-LOX-OH (Fig. 5D) . Given that the formation of trans-or cis-F-LOX-OH was associated with concomitant loss of F-LOX and the sum of F-LOX, trans-F-LOX-OH and cis-F-LOX-OH was consistent throughout the incubation (Fig. 5D ), it appears that the homogenates metabolized F-LOX selectively to trans-F-LOX-OH and cis-F-LOX-OH. Incubation of trans-F-LOX-OH or cis-F-LOX-OH with the homogenates generated F-LOX and the conversion from trans-F-LOX-OH was more efficient that from cis-F-LOX-OH (Figs. 5E and 5F ). Furthermore, although the incubation of cis-F-LOX-OH with the homogenates generated trans-F-LOX-OH, the opposite did not occur (Figs. 5E and 5F). These results correlate well with the in vivo findings illustrated in Figures 3 and 4 . The results in Figure 5 suggest that there is a metabolic system that converts F-LOX and LOX preferentially to their trans-OH rather than cis-OH forms.
Results in Figure 5 show that the disappearance rate of F-LOX was similar to that of LOX. Therefore, the more rapid clearance of F-LOX than LOX that was observed in vivo could not be explained by its metabolic conversion in the liver. The examination of the urinary clearance and protein binding would be required to understand the mechanism for the difference in pharmacokinetics between the two drugs.
Production of gastric lesions by F-LOX and LOX: We have previously reported that F-LOX produces fewer gastric lesions than LOX in rats, and proposed that this lower ulcerogenic activity of F-LOX is due to its lower membrane permeabilization activity. 26) However, given that the results demonstrate that F-LOX and its active metabolite (trans-F-LOX-OH) disappear from the plasma more rapidly than LOX, it is also possible that the lower ulcerogenic activity of F-LOX is due to its lower plasma level after a Figure 4 were used to calculate each pharmacokinetic parameter as described in Methods. Values are mean « S.D. (n = 4-6). *p < 0.05, **p < 0.01 (vs. LOX and its metabolites). single oral administration. To test this possibility, we performed the experiments illustrated in Figure 6 . In this study, in order to keep the plasma concentration of F-LOX higher than that of LOX, rats were either administered a 3-fold higher dose of F-LOX than LOX or administered the same dose of F-LOX as LOX but at 3 time-points (0, 1 and 4 h) (Fig. 6A) . As shown in Figure 6B , a consistently higher plasma concentration of F-LOX than LOX was achieved using these protocols. Administration of F-LOX produced fewer gastric lesions than LOX in all cases (Fig. 6C) , strongly suggesting that the lower ulcerogenic activity of the former drug cannot be explained by the differences in its pharmacokinetic characteristics. In other words, the lower ulcerogenic activity of F-LOX seems to be derived from other properties, such as its lower membrane permeabilization activity. Conclusions: In this study, we compared the pharmacokinetics of F-LOX and LOX. Although some differences were observed, it should be noted that the pharmacokinetic characteristics of F-LOX are basically comparable to those of LOX. In particular, it is important to note that the metabolic conversion characteristics of the ketone, trans-OH-and cis-OH forms of LOX were maintained in F-LOX, given that the pro-drug properties of LOX are believed to play important roles in its clinically beneficial effects, including its potent anti-inflammatory action and low gastrointestinal side effect. Therefore, the results in this study confirm the idea that F-LOX is a LOX analog with reduced gastrointestinal side effects and suggest that it is likely to be a therapeutically safer NSAID.
